Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 1.00 |
| ▸ | BRD4 | O60885 | 3/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4915591 | 0.95 | MAPK14 (1.00) | MAPK14BRD4BRDT | |
| SCHEMBL4914492 | 0.93 | MAPK14 (1.00) | MAPK14BRD4BRDT | |
| SCHEMBL6943923 | 0.92 | MAPK14 (1.00) | MAPK14BRD4BRDT | |
| SCHEMBL4593956 | 0.91 | MAPK14 (1.00) | MAPK14BRD4BRDT | |
| SCHEMBL4917866 | 0.91 | MAPK14 (1.00) | MAPK14BRD4BRDT | |
| SCHEMBL4906584 | 0.91 | MAPK14 (1.00) | MAPK14BRD4BRDT | |
| SCHEMBL6947846 | 0.91 | MAPK14 (1.00) | MAPK14BRD4BRDT | |
| SCHEMBL22730509 | 0.91 | MAPK14 (0.83) | MAPK14BRD4BRDT | |
| SCHEMBL4912070 | 0.91 | MAPK14 (1.00) | MAPK14BRD4BRDT | |
| SCHEMBL6949284 | 0.90 | MAPK14 (1.00) | MAPK14BRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0996446-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | claimed |
| US-6562832-B1 | Cytokine suppressive anti-inflammatory drugs, capable of inhibiting the CSBP/p38/RK kinase | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | claimed |
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-12-03 | — | — | US | disclosed |
| EP-0996446-B1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6562832-B1 | Cytokine suppressive anti-inflammatory drugs, capable of inhibiting the CSBP/p38/RK kinase | SMITHKLINE BEECHAM CORPORATION | 2003-05-13 | — | — | US | disclosed |
| EP-0996446-A4 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-0996446-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-05-03 | — | — | EP | disclosed |
| US-6046208-A | TREATMENT OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, ENDOTOXEMIA AND/OR TOXIC SHOCK SYNDROME, OTHER ACUTE OR CHRONIC INFLAMMATORY DISEASE STATES SUCH AS THE INFLAMMATORY REACTION INDUCED BY ENDOTOXIN OR INFLAMMATORY BOWEL DISEASE | SMITHKLINE BEECHAM CORPORATION (US) | 2000-04-04 | — | — | US | disclosed |
| WO-1999001131-A1 | NOVEL SUBSTITUTED IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377474-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | BRDT, BRD4, BRD3 | MAPK14 2751/4885BRD4 2/4885BRDT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.